Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Informed Consent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28,960 result(s) found for: Informed Consent. Displaying page 716 of 1,448.
    «« First « Previous 712  713  714  715  716  717  718  719  720  Next» Last»»
    EudraCT Number: 2005-000051-15 Sponsor Protocol Number: A4061008 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: Continuing Access to the Tyrosine Kinase Inhibitor of VEGFR-2, AG-013736 (A406) for Patients Previously Receiving AG-013736 in Clinical Trials
    Medical condition: Patients who have been treated in previous AG-013736 oncology studies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-003914-42 Sponsor Protocol Number: CEFTAROLINE_RRT Start Date*: 2013-11-06
    Sponsor Name:Medizinische Universität Wien, Univ.-Klinik für Innere Medizin I, Klinische Abteilung für Infetionen und Tropenmedizin
    Full Title: Multiple-dose Pharmacokinetics of Ceftaroline during continuous and intermittent renal replacement therapy in patients requiring renal replacement therapy
    Medical condition: Bacterial infection in patients recieving renal replacement therapy
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10060945 Bacterial infection PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2025-000141-10 Sponsor Protocol Number: EBSI-CV-317-006 Start Date*: 2025-06-02
    Sponsor Name:Bavarian Nordic A/S
    Full Title: EBSI-CV-317-006: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 2 to <12 Years of Age
    Medical condition: Healthy Volunteers (Chikungunya disease. Prevention of Chikungunya disease by use of a vaccine.)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10067256 Chikungunya virus infection PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2021-005906-83 Sponsor Protocol Number: LYR-210-2021-004 Start Date*: 2022-08-05
    Sponsor Name:Lyra Therapeutics, Inc.
    Full Title: ENLIGHTEN 1: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults
    Medical condition: Chronic Rhinosinusitis (CRS) in Adults
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10009137 Chronic sinusitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) ES (Ongoing) AT (Completed)
    Trial results: View results
    EudraCT Number: 2025-000142-26 Sponsor Protocol Number: 217091 Start Date*: 2025-04-29
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Multi-Centre, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Subcutaneously Administered Belimumab Plus Standard Therapy in Chinese Paediatric Participants with Systemic Lupus Er...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-001372-37 Sponsor Protocol Number: ET13-024 Start Date*: 2014-06-13
    Sponsor Name:CENTRE LEON BERARD
    Full Title: A randomized, multicentre, phase III trial evaluating the interest of imatinib treatment maintenance or interruption after 3 years of adjuvant treatment in patients with Gastrointestinal Stromal Tu...
    Medical condition: GastroIntestinal Stromal Tumours (GIST)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001034-18 Sponsor Protocol Number: PETMR-Staging-PCa1 Start Date*: 2020-03-04
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Phase II monocentric study to evaluate a novel approach for staging prostate cancer patients by using a fully integrated hybrid PET/MRI
    Medical condition: Patient diagnosed with prostatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013126-16 Sponsor Protocol Number: TMC125-TiDP35-C239 Start Date*: 2009-11-09
    Sponsor Name:Tibotec Pharmaceuticals c/o Tibotec BVBA
    Full Title: Continued access to etravirine in treatment experienced HIV-1 infected children and adolescents.
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020192 HIV-1 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004656-14 Sponsor Protocol Number: BGB-A317-A1217-301 Start Date*: 2021-11-02
    Sponsor Name:BeiGene, Ltd.
    Full Title: Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiotherapy (cCRT) Followed by Ociperlimab Plus Tislelizumab or Tislelizu...
    Medical condition: Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) NL (Completed) PL (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002121-30 Sponsor Protocol Number: 1704R2133 Start Date*: 2020-04-17
    Sponsor Name:Shionogi B.V.
    Full Title: An Open-label Study with a Nonrandomized Single-dose Phase in Subjects with Suspected or Confirmed Aerobic Gram-negative Bacterial Infections followed by a Randomized, Multiple-dose, Active-control...
    Medical condition: Single dose: Pneumonia, cUTI, complicated intra-abdominal infections [cIAI], hospital acquired bacterial pneumonia [HABP]/ventilator-associated bacterial pneumonia [VABP], and sepsis or bloodstream...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    20.0 10021881 - Infections and infestations 10076918 Hospital acquired pneumonia LLT
    20.1 10021881 - Infections and infestations 10065153 Ventilator associated pneumonia LLT
    20.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    24.1 10021881 - Infections and infestations 10003997 Bacteraemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) GR (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-006083-57 Sponsor Protocol Number: CA184-025 Start Date*: 2006-10-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols Revised Protocol...
    Medical condition: Stage III, IV metastatic advanced melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DE (Prematurely Ended) AT (Completed) HU (Completed) FI (Completed) SE (Completed) IT (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-003131-11 Sponsor Protocol Number: 1280-0022 Start Date*: 2018-12-11
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: XeneraTM-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemest...
    Medical condition: HR+ / HER2- metastatic breast cancer and non-visceral disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) GR (Completed) PT (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000621-80 Sponsor Protocol Number: 212082BCA2001 Start Date*: 2011-08-01
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or ...
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed) ES (Completed) FR (Completed) NL (Prematurely Ended) IE (Completed) IT (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002067-41 Sponsor Protocol Number: 3475-158 Start Date*: 2016-01-14
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
    Medical condition: -Anal Squamous Cell Carcinoma (CA)-Biliary Adenocarcinoma -Neuroendocrine Tumors (well-and moderately-differentiated) -Endometrial CA (sarcomas and mesenchymal tumors are excluded) -Cervical Squamo...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001775-41 Sponsor Protocol Number: UX023-CL304 Start Date*: 2015-12-16
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults with X-linked Hypophosphatemia (XLH)
    Medical condition: XLH is a disorder of hypophosphatemia, renal phosphate wasting, and the most common inheritable form of rickets. In XLH patients, excess circulating fibroblast growth factor (FGF23) impair phospha...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10016206 Familial hypophosphataemic rickets LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006441-10 Sponsor Protocol Number: 116-02 Start Date*: 2009-06-03
    Sponsor Name:SCIPHARM SáRL
    Full Title: A double blind controlled clinical study to investigate the efficacy and tolerability of subcutaneous Treprostinil sodium in patients with severe non-operable Chronic Thromboembolic Pulmonary Hyper...
    Medical condition: Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) SK (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002527-21 Sponsor Protocol Number: AMYPAD-01 Start Date*: 2018-05-23
    Sponsor Name:University of Geneva
    Full Title: Multicentre, Open-label, Randomised Study to Assess the Diagnostic Value of Amyloid PET Imaging in Patients with Subjective Cognitive Decline Plus, Mild Cognitive Impairment, or Dementia Where Alzh...
    Medical condition: Alzheimer's disease Mild Cognitive Impairment Subjective Cognitive Decline Plus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022548-19 Sponsor Protocol Number: TP-434-P2-cIAI-1 Start Date*: 2011-05-09
    Sponsor Name:Tetraphase Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of 2 Dose Regimens of TP-434 Compared with Ertapenem in Adult...
    Medical condition: Community-acquired complicated intra-abdominal infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BG (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003553-19 Sponsor Protocol Number: IBCSG59-19/BIG18-02 Start Date*: 2019-06-25
    Sponsor Name:International Breat Cancer Study Group (IBCSG)
    Full Title: A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2...
    Medical condition: patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002267-29 Sponsor Protocol Number: WVE-004-002 Start Date*: 2022-10-14
    Sponsor Name:Wave Life Sciences UK Limited
    Full Title: A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-004 in Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and...
    Medical condition: Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) IE (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 712  713  714  715  716  717  718  719  720  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 11:58:20 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA